{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:57:12Z","timestamp":1793642232362,"version":"4.5.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N003322\/1"],"award-info":[{"award-number":["MR\/N003322\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Versus Arthritis Programme","award":["18474"],"award-info":[{"award-number":["18474"]}]},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biomedical Research Centre Funding Scheme"},{"DOI":"10.13039\/100004856","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the role of the anti-TIF1\u03b3 auto-antibody (aAb) IgG2 isotype as a biomarker of cancer in anti-TIF1\u03b3 aAb-positive adult DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>International multicentre retrospective study with the following inclusion criteria: (i) diagnosis of DM according to ENMC criteria; (ii) presence of anti-TIF1\u03b3 IgG aAb determined using an in-house addressable laser bead immunoassay (ALBIA) from cryopreserved serums sampled at time of DM diagnosis and (iii) available baseline characteristics and follow-up data until the occurrence of cancer and\/or a minimum follow-up of 1\u2009year for patients without known cancer at diagnosis. Detection and quantification of anti-TIF1\u03b3 IgG2 aAb was done using the in-house ALBIA. In addition, a recent ELISA commercial kit was used for anti-TIF1\u03b3 IgG aAb quantification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 132 patients (mean age 55\u00b115\u2009years) of whom 72 (54.5%) had an associated cancer were analysed. The association between the presence of cancer and the presence of anti-TIF1\u03b3 IgG2 aAb was statistically significant (P\u2009=\u20090.026), with an OR of 2.26 (95% CI: 1.10, 4.76). Patients with cancer displayed significantly higher anti-TIF1\u03b3 IgG2 aAb ALBIA values with a median value of 1.15\u2009AU\/ml (IQR: 0.14\u20139.76) compared with 0.50\u2009AU\/ml (IQR: 0.14\u20131.46) for patients without cancer (P\u2009=\u20090.042). In addition, patients with cancer displayed significantly higher anti-TIF1\u03b3 IgG aAb ELISA values with a median value of 127.5\u2009AU\/ml (IQR: 81.5\u2013139.6) compared with 93.0\u2009AU\/ml (IQR: 54.0\u2013132.9) for patients without cancer (P\u2009=\u20090.004).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results suggest considering anti-TIF1\u03b3 IgG2 ALBIA and IgG ELISA values as biomarkers of cancer in anti-TIF1 \u03b3 aAb-positive adult DM.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keac577","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T18:41:39Z","timestamp":1666032099000},"page":"1711-1715","source":"Crossref","is-referenced-by-count":14,"title":["Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1679-8005","authenticated-orcid":false,"given":"Nad\u00e8ge","family":"Cordel","sequence":"first","affiliation":[{"name":"Department of Dermatology and Clinical Immunology, Guadeloupe University Hospital , Pointe-\u00e0-Pitre, Guadeloupe"},{"name":"Univ Rouen Normandie, FOCIS Center of Excellence PAn\u2019THER, Inserm, U1234 , Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Dechelotte","sequence":"additional","affiliation":[{"name":"Univ Rouen Normandie, FOCIS Center of Excellence PAn\u2019THER, Inserm, U1234 , Rouen, France"},{"name":"Department of Immunology and Biotherapy, Rouen University Hospital , Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Jouen","sequence":"additional","affiliation":[{"name":"Univ Rouen Normandie, FOCIS Center of Excellence PAn\u2019THER, Inserm, U1234 , Rouen, France"},{"name":"Department of Immunology and Biotherapy, Rouen University Hospital , Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine A","family":"Lamb","sequence":"additional","affiliation":[{"name":"Epidemiology and Public Health Group, School of Health Sciences, University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-1288","authenticated-orcid":false,"given":"Hector","family":"Chinoy","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester , Manchester, UK"},{"name":"Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Salford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"New","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Vencovsky","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology , Na Slupi 4 , Praha 2, Czech Republic"},{"name":"Department of Rheumatology, 1st Medical Faculty, Charles University , Praha, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Mann","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology , Na Slupi 4 , Praha 2, Czech Republic"},{"name":"Department of Rheumatology, 1st Medical Faculty, Charles University , Praha, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-211X","authenticated-orcid":false,"given":"Angeles S","family":"Galindo-Feria","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Karolinska Institute Stockholm , Solna, Sweden"},{"name":"ME Gastro, Derm, Rheuma, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Dani","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Karolinska Institute Stockholm , Solna, Sweden"},{"name":"ME Gastro, Derm, Rheuma, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2823-9761","authenticated-orcid":false,"given":"Albert","family":"Selva-O\u2019Callaghan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vall d'Hebron Hospital, Universitat Aut\u00f2noma Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P","family":"Werth","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania and Corporal Michael L. Creszenc (PHL) VAMC , Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Ravishankar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania and Corporal Michael L. Creszenc (PHL) VAMC , Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oc\u00e9ane","family":"Landon-Cardinal","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Montreal , Montreal, Quebec, Canada"},{"name":"Division of Rheumatology and Research Center, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al , Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Tressi\u00e8res","sequence":"additional","affiliation":[{"name":"Centre d'Investigation Clinique Antilles Guyane, INSERM CIC 1424 , Pointe-\u00e0-Pitre, Guadeloupe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Boyer","sequence":"additional","affiliation":[{"name":"Univ Rouen Normandie, FOCIS Center of Excellence PAn\u2019THER, Inserm, U1234 , Rouen, France"},{"name":"Department of Immunology and Biotherapy, Rouen University Hospital , Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"e94128","DOI":"10.1371\/journal.pone.0094128","article-title":"Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta- analysis","volume":"9","author":"Lu","year":"2014","journal-title":"PLoS One"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jdv.14759","article-title":"Distinctive cutaneous and systemic features associated with specific anti-myositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients","volume":"32","author":"Best","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-\u03b3 antibody and cancer-associated myositis: a clinicohistopathologic study","volume":"87","author":"Hida","year":"2016","journal-title":"Am Ac Neurology"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2340\/00015555-3091","article-title":"Usefulness of anti-transcriptional intermediary factor-1 gamma (TIF1\u03b3) autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis","volume":"99","author":"Best","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/art.40895","article-title":"The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis","volume":"71","author":"Aussy","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th workshop study group: classification of dermatomyositis, Amsterdam, the Netherlands 14\u201316 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3899\/jrheum.140566","article-title":"Polymyositis\/dermatomyositis and malignancy risk: a meta analysis study","volume":"42","author":"Yang","year":"2015","journal-title":"J Rheumatol"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"e9639","DOI":"10.1097\/MD.0000000000009639","article-title":"Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts","volume":"97","author":"Leatham","year":"2018","journal-title":"Medicine"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jalm\/jfab140","article-title":"The International Consensus on ANA Patterns (ICAP) in 2021-the 6th workshop and current perspectives","volume":"7","author":"Chan","year":"2022","journal-title":"J Appl Lab Med"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fimmu.2017.00992","article-title":"Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer","volume":"8","author":"Aussy","year":"2017","journal-title":"Front Immunol"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"804037","DOI":"10.3389\/fimmu.2022.804037","article-title":"A Commercial Anti-TIF1\u03b3 ELISA is superior to Line and Dot Blot and should be considered as part of routine myositis-specific antibody testing","volume":"13","author":"Mulhearn","year":"2022","journal-title":"Front Immunol"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoasays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3389\/fimmu.2016.00410","article-title":"Evaluation of the antigen-experienced B-Cell receptor repertoire in healthy children and adults","volume":"7","author":"IJspeert","year":"2016","journal-title":"Front Immunol"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1093\/rheumatology\/keab260","article-title":"TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1\u03b3 positive cancer-associated dermatomyositis","volume":"60","author":"Cordel","year":"2021","journal-title":"Rheumatology"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology"},{"key":"2023040420423866900_","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/rheumatology\/kez572","article-title":"Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen","volume":"59","author":"De Vooght","year":"2020","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac577\/46874712\/keac577.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/4\/1711\/49750845\/keac577.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/4\/1711\/49750845\/keac577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T21:51:24Z","timestamp":1701208284000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/4\/1711\/6762097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac577","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,10,17]]}}}